Calidi Biotherapeutics, Inc. - Schedule 13D Filing

Ognian Anguelov Gavrilov, a US citizen and Managing Partner at Gavrilov & Brooks, has acquired 700,000 shares of Calidi Biotherapeutics, Inc. common stock, representing 9.8% ownership. The acquisition was funded by personal funds and is for investment purposes. Gavrilov may acquire or dispose of additional shares in the future. The filing also notes that no other person has the right to receive or direct the receipt of dividends or proceeds from the sale of these securities. The filing was made on March 9, 2026.